HRTX News and Press, Heron Therapeutics Inc. From 05/28/21

Heron Therapeutics (HRTX) has filed for an offering of up to 12.4M shares of common stock from a shareholder.The maximum aggregate offering price is $172.3M.Heron shares are down 1.9% to $13.02 in after-hours trading. For further details see: Heron Therapeutics files for 12.4M...

Heron Therapeutics to Present at the 2021 Jefferies Virtual Investor Conference PR Newswire SAN DIEGO , May 25, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients ...

Biotech Stocks Remain A Core Focus For Traders This Year Penny stocks are well-known for their volatility. In one moment, you can see them gaining hundreds of percentage points. Then the next moment, you see them hitting new lows. Is this the case for all penny stocks ? No, but this...

Heron Therapeutics ([[HRTX]] -0.1%) announced the sale of $150 million of senior unsecured convertible promissory notes in a private placement.The notes due June 01, 2026, will carry an interest rate of 1.5% per annum payable semiannually.The senior, unsecured obligations ...

Heron Therapeutics Announces $150 Million Convertible Debt Financing PR Newswire SAN DIEGO , May 25, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron") today announced that it has sold $150 million of senior unsecured convertible promissor...

Heron finally received FDA approval for Zynrelef but it came with a surprisingly narrow label. The company believes it can secure a broad label with additional studies but the narrow label will likely impact Zynrelef's growth trajectory. The CINV franchise is expected to start to ...

Heron Therapeutics finally got its long sought after and anticipated FDA approval for ZYNRELEF last week. However, the stock fell due to some restrictive labeling and some 'buy the rumor, sell the news' trading action. What is the proper investing action post-FDA approval/stock de...

Fate's early stage data look promising: JefferiesFate Therapeutics (FATE) shares shed ~1.4% after the company announced data from an early stage leukemia trial for its natural killer ((NK)) cell programs.Fate has lost ~21.3% in the year so far and noting that data looked promising and have de...

Heron Therapeutics (HRTX) has added ~16.6% in the premarket after announcing that its postoperative painkiller ZYNRELEF (bupivacaine and meloxicam) was approved by the FDA.Given the side effects, the regulator has licensed ZYNRELEF with a Boxed Warning and it is indicated for &...

Palisade Bio (PALI) +36% on FDA's fast track designation for LB1148.Fuel Tech (FTEK) +21% on Q1 results.Lianluo Smart (LLIT) +20%.Celyad Oncology SA (CYAD) +20%.Vertex Energy (VTNR) +18% on Q1 results.InnSuites Hospitality Trust (IHT) +15%.Heron Therapeutics (HRTX) +15% on...